HIGHLIGHTS
- What: The authors report the case of a 67-year-old man who received pembrolizumab for postoperative lymph node recurrence of gastric cancer.
- Who: Shusaku Honma and collaborators from the (UNIVERSITY) have published the research: Review began 07/26/2024 Review ended 08/03/2024 Published 08/08/2024 © Copyright, in the Journal: (JOURNAL) of August/08,/2024
- Future: Studies are needed to establish the optimal management of irSCs and to identify biomarkers that have the potential to accurately predict the risk of irAE development in patients undergoing ICI treatment.
SUMMARY . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.